VALN - Valneva plays down findings on its COVID-19 vaccine in U.K. booster study

Valneva SE (VALN -15.0%) blamed the design of a booster trial in the U.K. after its peer-reviewed data indicated that the company’s experimental COVID-19 vaccine underperformed rivals when given as a booster to those who received Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) vaccine initially. While the vaccine performed well alongside others when administered as a booster 10 – 12 weeks after the initial regimen of the AstraZeneca (NASDAQ:AZN) vaccine, the lack of booster effect for recipients of a widely used vaccine has caused investor concerns with Valneva (NASDAQ:VALN) ADRs trading lower. The French biotech says that the vaccines based on inactivated viruses such as its candidate, VLA2001, require a longer gap for optimal effect. "Valneva believes it is likely that the short interval between the second shot and booster shot could have adversely impacted the results for VLA2001, given that a longer interval is generally required for inactivated vaccines," the company told Reuters in a statement. The

For further details see:

Valneva plays down findings on its COVID-19 vaccine in U.K. booster study